Noticias de HALO_US | Rava Bursátil

07/10/2026 HALO_US — Investing.com

Halozyme stock rises after winning injunction against Merck

07/10/2026 HALO_US — Yahoo Finance

Halozyme Therapeutics, Inc. (HALO) Stock Forecasts

07/10/2026 HALO_US — Seeking Alpha

Merck’s injectable Keytruda barred in Europe as Halozyme wins injunction

Merck (MRK) stock slips as the Dutch court blocks injectable Keytruda in key European markets after the Halozyme (HALO) patent dispute. Read more here.

07/10/2026 HALO_US — Yahoo Finance

Halozyme stock rises after winning injunction against Merck

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck

07/10/2026 HALO_US — Bloomberg

Merck’s New Keytruda Shot Blocked in Europe After Court Loss

06/10/2026 HALO_US — Lelezard

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

06/10/2026 HALO_US — Simply Wall Street

HALO - The $300+ Runway: Why Halozyme’s Pipeline Transition Erases the Patent Cliff

06/10/2026 HALO_US — Yahoo Finance

Halozyme Therapeutics, Inc. (HALO) Stock forecasts

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

06/10/2026 HALO_US — Investing.com

Halozyme expands argenx collaboration with two new targets By Investing.com

06/10/2026 HALO_US — Investing.com

Halozyme expands argenx collaboration with two new targets By Investing.com

06/10/2026 HALO_US — MarketScreener

Halozyme Therapeutics, Inc. And Argenx Announce Expansion Of Global Collaboration And License Agreement To Support The Development Of Subcutaneous Formulations For Two Additional Exclusive Targets Using ENHANZE® Technology

06/10/2026 HALO_US — AD HOC NEWS

Halozyme director sells 5,230 shares of Halozyme stock

Revenue reached USD 481.00 million in the second quarter, up 47.70 percent. Halozyme stock costs EUR

06/10/2026 HALO_US — Stock Titan

A drug-delivery partnership expands from six exclusive targets to eight.

Halozyme is eligible for milestone payments when agreed milestones are met, plus royalties on net sales of products using ENHANZE for subcutaneous formulations.

06/10/2026 HALO_US — Simply Wall Street

Halozyme Therapeutics (Nasdaq:HALO) - Stock Analysis

06/10/2026 HALO_US — PR Newswire

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

/PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and...

06/10/2026 HALO_US — Investing.com

Halozyme expands argenx collaboration with two new targets

05/10/2026 HALO_US — ChartMill

Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup

02/10/2026 HALO_US — MarketScreener

Halozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC Filing

02/10/2026 HALO_US — StreetInsider

Form 3 HALOZYME THERAPEUTICS, For: Sep 28 Filed by: Daly James M

02/10/2026 HALO_US — AD HOC NEWS

Halozyme prices USD 1.30 billion notes and Halozyme Therapeutics stock gains 2.61 percent

Q2 revenue hit USD 481.00 million, up 47.70 percent year over year. Halozyme Therapeutics stock cost